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Evidence of inflammation has been consistently associated with pathology in Parkinson’s
disease (PD)-affected brains, and has been suggested as a causative factor.
Dopaminergic neurons in the substantia nigra (SN) pars compacta, whose loss results in
the clinical symptoms associated with PD, are particularly susceptible to inflammatory
damage and oxidative stress. Inflammation in the striatum, where SN dopaminergic
neurons project, is also a feature of PD brains. It is not known whether inflammatory
changes occur first in striatum or SN. Many animal models of PD have implicated
certain inflammatory molecules with dopaminergic cell neuronal loss; however, there have
been few studies to validate these findings by measuring the levels of these and other
inflammatory factors in human PD brain samples. This study also included samples from
incidental Lewy body disease (ILBD) cases, since ILBD is considered a non-symptomatic
precursor to PD, with subjects having significant loss of tyrosine hydroxylase-producing
neurons. We hypothesized that there may be a progressive change in key inflammatory
factors in ILBD samples intermediate between neurologically normal and PD. To address
this, we used a quantitative antibody-array platform (Raybiotech-Quantibody arrays) to
measure the levels of 160 different inflammation-associated cytokines, chemokines,
growth factors, and related molecules in extracts of SN and striatum from clinically
and neuropathologically characterized PD, ILBD, and normal control cases. Patterns
of changes in inflammation and related molecules were distinctly different between SN
and striatum. Our results showed significantly different levels of interleukin (IL)-5, IL-15,
monokine induced by gamma interferon, and IL-6 soluble receptor in SN between
disease groups. A different panel of 13 proteins with significant changes in striatum,
with IL-15 as the common feature, was identified. Although the ability to detect some
proteins was limited by sensitivity, patterns of expression indicated involvement of certain
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T-cell cytokines, vascular changes, and loss of certain growth factors, with disease
progression. The results demonstrate the feasibility of profiling inflammatory molecules
using diseased human brain samples, and have provided additional targets to validate in
relation to PD pathology.
Keywords: inflammation, pathology, cytokines, antibody array, dopaminergic cell loss, Parkinson’s disease,
microglia, astrocytes
INTRODUCTION
Parkinson’s disease (PD) is a chronic, progressive
neurodegenerative disorder characterized by symptoms of
tremor, bradykinesia, ataxia and rigidity, and is the main cause
of movement disorders in the elderly. The current estimates
of PD are one million cases in the U.S.A. with 60,000 cases
being added each year (Parkinson’s Disease Foundaton, 2015).
This leads to significant morbidity and mortality in affected
individuals along with the considerable cost of healthcare
for PD patients. Sufferers of PD also have significant risk of
progressing to dementia (Aarsland et al., 2005). There have
been major strides in understanding the cause(s) of PD, but
there is still lack of consensus of the sequence of events that
lead to the loss of the dopaminergic neurons of the substantia
nigra (SN) pars compacta and results in loss of dopaminergic
neurotransmission in the striatum. Much research on disease
mechanisms has focused on the properties of the presynaptic
vesicle protein α-synuclein whose modifications can lead to the
formation of aggregated and neurotoxic species (Vekrellis and
Stefanis, 2012; Lawand et al., 2015; Osterberg et al., 2015; Sian-
Hulsmann et al., 2015). Aggregated α-synuclein, particularly the
phosphorylated form, is the major component of Lewy bodies,
the major pathological feature of PD brains (Fujiwara et al.,
2002). Most of the identified mutations in α-synuclein appear to
increase the risk of PD by increasing its tendency to aggregate
(Polymeropoulos, 1997; Baba et al., 1998; Conway et al., 1998;
Ancolio et al., 2000; Ostrerova-Golts et al., 2000; Ghosh et al.,
2013; Giráldez-Pérez et al., 2014).
Inflammation has also been a well-established feature of
PD pathology (McGeer et al., 1988; Boka et al., 1994; Mogi
et al., 1994; Hunot et al., 1999; Brochard et al., 2009), and
some data have suggested it could be the primary pathological
cause for SN neuronal cell death (Tansey et al., 2007, 2008;
Vivekanantham et al., 2015). Inflammation in PD brains could be
caused by different factors, but a number of studies have shown
that aggregated forms of α-synuclein can activate microglia
to produce toxic molecules that contribute to dopaminergic
cell death (Zhang et al., 2005; Couch et al., 2011; Béraud
et al., 2013; Acosta et al., 2015). Alpha-synuclein activation of
microglia can be mediated through the Toll-like receptor (TLR)-
2 (Codolo et al., 2013; Kim et al., 2013; Doorn et al., 2014;
Daniele et al., 2015), though other microglial receptors have
also been implicated, including TLR-4 (Stefanova et al., 2011;
Fellner et al., 2013) and purinergic receptor P2X7 (Jiang et al.,
2015). A recent immunohistochemical study of SN from control,
ILBD and PD cases for the inflammation marker TLR-2 showed
increased numbers of TLR-2-positive microglia in ILBD cases
compared to PD cases (Doorn et al., 2014). This suggested
that some inflammatory changes could be happening at early
stages prior to development of symptoms of PD. By contrast,
there was progressive increase from control to PD in numbers
of CD68-positive amoeboid microglia/macrophages, a marker
associated with phagocytosis, which correlated with an increase
in α-synuclein deposits (Doorn et al., 2014). Independent of the
presence of pathological α-synuclein, the human SN appears
to be particularly sensitive to inflammation, possibly due to
higher concentrations of iron, and neuromelanin, both of which
can contribute to an environment of enhanced oxidative stress
(Hirsch, 1993; Béraud et al., 2013; Taylor et al., 2013; Fischer
and Maier, 2015). Purified neuromelanin can directly activate
microglia to a proinflammatory state (Wilms et al., 2003; Zhang
et al., 2013).
Animal models for PD have provided the most convincing
evidence for how inflammation could be directly linked
to SN neuronal cell loss. A widely used model involves
the administration of the bacterial cell wall extract
lipopolysaccharide (LPS) (Couch et al., 2011; Qin et al.,
2013; Tanaka et al., 2013; Sharma and Nehru, 2015). Both direct
injection of LPS into the SN or by intraperitoneal injection
can lead to enhanced inflammation in the brain and selective
loss of SN neurons. Administration of LPS results in increased
production of free radicals and potentially toxic cytokines,
including tumor necrosis factor-α (TNF-α) (McGuire et al.,
2001; Pei et al., 2007; Tansey et al., 2007, 2008; Zhao et al., 2007;
Gao et al., 2011; Tran et al., 2011; Montgomery and Bowers,
2012; Qin et al., 2013). Another feature of inflammation-induced
models of PD is disruption of the blood-brain barrier, which
enhances inflammation by permitting influx of components of
cell-mediated immunity (Carvey et al., 2005b, 2006; Desai et al.,
2007; Monahan et al., 2008).
The spread of abnormal forms of α-synuclein along
neuroanatomical pathways is a significant pathological
mechanism in humans and animal models of synucleinopathies
(Beach et al., 2009; Luk et al., 2012; Masuda-Suzukake et al., 2014;
Paumier et al., 2015). In animal models, instrastriatal injection
of preformed α-synuclein fibrils resulted in neurodegeneration
and inflammation in the SN; the reverse effect occurs with
α-synuclein administered into the SN resulting in striatum
pathology and inflammation (Koprich et al., 2010; Luk et al.,
2012; Osterberg et al., 2015; Paumier et al., 2015). Direct
injection of LPS into striatum or SN resulted in degeneration of
nigrostriatal pathway neurons and motor impairments, along
with microglial activation (Choi et al., 2009; Couch et al., 2011).
Co-administration of α-synuclein and LPS can significantly
enhance the generation of nigrostriatal pathology (Couch et al.,
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2011; Gao et al., 2011). As it is still not known if spread of
pathology or neuroinflammation occurs from striatum to SN
or vice-versa, as part of this study, we sought to compare the
changes in inflammation and trophic molecules between SN and
striatum with disease progression. Recent mouse models of PD
have focused on α-synuclein, either overexpression of normal or
mutated α-synuclein under transgene control or overexpression
by administration of α-synuclein viral transduction vectors
(Watson et al., 2012; Béraud et al., 2013; Gardai et al., 2013;
Harms et al., 2013). Animal models of PD can also be developed
using the dopaminergic neurotoxin 1-methyl-4 phenyl-1,2,3,6-
tetrahydropyridine (MPTP) to lesion the SN and striatum. This
model can reproduce many PD features in non-human primates
(Ohnuki et al., 2010). This study carried out gene expression
profiling of SN and striatum tissue and showed significant
downregulation of neuronal and dopaminergic genes in lesioned
animals. With respect to inflammation-related genes, only
upregulation of glial fibrillary acidic protein (GFAP), interleukin
(IL)-11, and chemokines CXCL13 and CXCL4 were detected
(Ohnuki et al., 2010).
Although there have been many immunohistological studies
that used antibodies to activated microglia to demonstrate
inflammation in PD brains, there have been few studies
that biochemically measured levels of cytokines or other
inflammation-associated molecules in human brain samples
(Nagatsu et al., 2000a,b). A recent proteomics analysis comparing
SN tissue from PD and control cases identified cytosolic non-
specific dipeptidase 2 to be upregulated in PD tissue, but
not inflammatory or growth factor molecules. This may have
been due to lack of sensitivity of the methods employed to
detect these low-abundance molecules (Licker et al., 2012). Such
experiments are technically difficult as only low concentrations
of key molecules are present in tissue. Cerebrospinal fluid (CSF),
plasma and blood have also been used as surrogates to follow
brain changes in PD (Rocha et al., 2014), but these results have
generally been inconsistent between studies. Increased levels of
IL-2, IL-6, and TNF-α have been detected in CSF samples of
PD subjects compared to controls (Mogi et al., 1994, 1996).
Screening of sera from control, PD, multiple system atrophy and
corticobasal syndrome cases using a similar antibody array as
used in this study, showed only platelet-derived growth factor
(PDGF)-BB and prolactin having significant disease associated
differences (Mahlknecht et al., 2012). Measurement of cytokines
in CSF from PD and control cases identified significant changes
in the cytokines/growth factors vascular endothelial growth
factor (VEGF), placental growth factor (PIGF), soluble VEGF
receptor (sVEGFR2), and angiopoietin2 (ANG2), associated with
angiogenesis (Janelidze et al., 2015).
To address the problems of sensitivity, studies have used
mRNA gene expression profiling of PD SN tissue, or laser-
dissected SN dopaminergic neurons, to identify disease
differences. These techniques have high sensitivity for detecting
low-abundance gene expression, but there has been lack
of consensus on the PD-associated differentially expressed
genes between studies. However, these studies have identified
multiple pathways affected in PD, with downregulation of
genes associated with synaptic function, cytoskeletal function
and neuroprotection and also ubiquitin-proteosome and
mitochondrial function genes being features (Grünblatt et al.,
2004; Hauser et al., 2005; Mandel et al., 2005; Duke et al., 2006;
Elstner et al., 2009; Ohnuki et al., 2010; Gründemann et al.,
2011; Botta-Orfila et al., 2012). A microarray study focusing on
inflammatory gene expression in PD SN showed upregulation
of the microglial purinergic receptor P2X7 (a receptor for ATP),
colony stimulating factor-1 receptor (CSF1R), (a microglia
growth factor receptor), and nitric oxide synthase 3 (a vascular
marker) (Durrenberger et al., 2012).
With the development of high-sensitivity multiplex antibody
arrays and other proteomic techniques, it is possible to profile
large numbers of different biologically-active proteins in human
brain tissue or other biological samples. We used this approach
to examine the levels of 158 proteins in SN and striatum
of control, ILBD and PD cases to determine if there were
progressive changes in inflammation or related proteins. We
particularly sought to determine if any of the cytokines identified
in PD animal models could be validated in these human
tissues. Our results demonstrated distinctly different patterns
of inflammation and growth factor changes between SN and
striatum with disease.
MATERIALS AND METHODS
Brain Tissue Samples
Brain tissue samples for this study were provided by the
Banner Sun Health Research Institute Brain and Body Donation
Program. The Brain and Body Donation Program operated
with the approval of Western IRB (Puyallup, WA) under
contract as the Institutional Review Board of Banner Research.
A summary of the demographics of the cases is shown in
Table 1. There were SN samples from 16 controls, 21 ILBD,
and 18 PD cases; and striatum samples from 16 controls, 17
ILBD, and 16 PD cases. Tissue samples from both SN and
striatumwere not available for all cases—overlap of cases between
brain regions was 92%. The selection of control, ILBD and
PD cases used in this study was based on neuropathology
diagnosis with reference to clinical records, with a diagnosis
of Alzheimer’s disease (AD) as the principal exclusion criteria.
The degree of Lewy body (LB) pathology was assessed using a
histological staging scheme in each of 10 brain regions (Beach
et al., 2009). This involved obtaining a ranking score (0–4)
using phosphorylated-alpha synuclein stained sections from
each region. These numbers are summed to give Lewy body
pathology scores of 0–40 for each brain. Histological ranking
scores of plaques and tangles in five brain regions were used
to assess how much age-associated AD-type pathology was
present in each case (Beach et al., 2012; Table 1). This involved
obtaining a ranking score (0–3) using Thioflavin S-stained
tissue sections from entorhinal cortex, hippocampus, frontal,
parietal, and temporal cortex. These numbers are summed to
give plaque and tangle scores of 0–15 for each brain. Dementia
was present in a number of the PD cases (Table 1); however,
neuropathology and clinical records indicated this was not due
to AD.
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TABLE 1 | Demographic features of cases used in study.
Disease Type n Age Sex Dementia LB Plaques Tangles
(Mean + SD) M/F (D/MCI/CN) (Mean + SD) (Mean + SD)
SUBSTANTIA NIGRA
Control 16 81.2 ± 11.4 9/7 0/16 0 1.4 ± 1.8 2.4 ± 1.6
ILBD 21 86.8 ± 6.8 17/4 0/3/18 1-3 3.5 ± 4.6 3.9 ± 2.2
PD (DD 12.9; 1–26) 18 81.3 ± 6.2 12/6 7/3/8 2b-4 3.2+ 3.6 3.9 ± 2.1
STRIATUM
Control 16 81.4 ± 11.5 10/6 0/16 0 1.5 ± 1.9 2.5 ± 1.8
ILBD 17 85.2 ± 6.4 13/4 0/2/15 1–3 3.4 ± 3.8 3.2 ± 1.3
PD (DD 13.4; 1–26) 16 81.3 ± 6.2 12/6 7/2/7 2b–4 3.2+ 3.6 4.1 ± 2.1
ILBD, incidental Lewy body disease; PD, Parkinson’s disease; n, number of cases; M/F, male/female; LB, Lewy body staging score; Plaques, Plaque score; Tangles, tangle score; D,
demented; MCI, mild cognitive impairment; CN, cognitively normal; DD, disease duration/years—mean and range.
Tissue Preparation
Due to the limited amount of SN tissue available from
each case, SN tissue was provided as 15 consecutive frozen
(10µm) SN sections (∼6–10mg) cut from each block with
a cryostat and collected frozen. This approach to tissue
sample preparation allowed the selection of matched samples
containing approximately equivalent densities of SN pars
compacta neuromelanin-containing neurons. Frozen striatum
samples (20–30mg) were dissected from putamen at the level of
the lenticular nucleus.
Processing of Tissue Samples
Both series of tissue samples were extracted in six volumes
(w/v) of a proprietary extraction buffer compatible with the
Quantibody arrays (Raybiotech, Norcross, GA) supplemented
with protease/phosphatase inhibitors (Thermo-Fisher/Pierce).
Samples were briefly sonicated in extraction buffer and incubated
on ice with constant shaking for 30min. After centrifugation
(18,000 g/30min), the supernatants were collected for further
analysis. Protein concentrations were determined using a micro
BCA assay (Thermo-Fisher/Pierce). These same extracts were
also used to prepare western blot samples.
Tissue Analyses
Preliminary analyses of protein extracts were carried out using
western blotmethods for tyrosine hydroxylase (TH), as ameasure
of degree of dopaminergic neuron cell loss; for IBA-1, an
indicator of microglia abundance; for TLR-2 as a marker for
inflammation; and for glial fibrillary acidic protein (GFAP),
as an indicator of reactive astrocytosis. We employed our
standard published western blot methods using antibodies to
TH (Biolegend, Dedham, MA; rabbit polyclonal 1:2000 dilution);
to IBA-1 (Wako Chemicals, Richmond, VA, 1:2000); to TLR-2
(Abcam, Cambridge, MA; rabbit monoclonal 1:2500 dilution);
and to GFAP [BD Biosciences, Franklin Lakes, NJ; cocktail of
three different monoclonal antibodies (1:2000)] (Walker et al.,
2015a,b).
For the antibody array analysis, samples were processed
as a service by Raybiotech (Norcross, GA). For SN, each
sample protein concentration was adjusted to 500µg/ml, and
for striatum, each sample was adjusted to 1000µg/ml. These
were analyzed using 160 protein Quantibody arrays (catalog
number QAH-CAA-3000) composed of antibody-coated glass
slide arrays for detecting cytokines, chemokines, soluble receptor,
and growth factors. Table 2 shows the arrangement of the
proteins on the four separate array slides. Each protein had
a standard curve included with measurements from known
dilutions of purified standard protein. Each slide array contained
positive control samples that were used for normalization
purposes. Measurements were based on fluorescent intensity
of bound labeled antibodies to each spot, and calculated
from the mean of four spots/antibody. Slides were measured,
analyzed, and normalized to positive controls using Raybiotech
software. Final results were expressed as pg of protein/ml
extract.
Immunohistochemical Staining of SN and
Striatum Tissue Sections
To characterize features of microglia activation in tissues being
examined by antibody array analysis, 40µm paraformaldehyde-
fixed tissue sections of SN and striatum from control, ILBD and
PD cases were stained using antibodies LN3 (Abcam, Cambridge,
MA) and IBA-1 (Wako Chemicals, Richmond, VA). These are
well-established markers for activated microglia (LN3) or pan
microglia (IBA-1). Striatum sections were double-stained for
TH (Biolegend—rabbit polyclonal, 1:2000) using a two-color
method. Immunohistochemstry was carried out according to our
published procedures (Walker et al., 2009, 2015b).
Data Analysis
The validity of the standard curve for each protein was confirmed
by visual inspection of data. We found that standard curves for
basic fibroblast growth factor and insulin growth factor binding
protein-4 were unsatisfactory as the standard proteins did not
produce a suitable dose-response curve; the results obtained for
these proteins in tissue samples were excluded.
Data for each brain region samples were grouped as control,
ILBD and PD and analyzed by One-way analysis of variance
(ANOVA) usingGraphpad Prism 5 software (Graphpad software,
La Jolla, CA) without corrections for multiple comparisons. To
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TABLE 2 | Quantibody array component proteins.
Array-CHE Array-CYT Array-REC Array-GF
6Ckine BLC 4-1BB AR
Axl Eotaxin ALCAM BDNF
BTC Eotaxin-2 B7-1 bFGF
CCL28 G-CSF BCMA BMP-4
CTACK GM-CSF CD14 BMP-5
CXCL16 I-309 CD30 BMP-7
ENA-78 ICAM-1 CD40 L b-NGF
Eotaxin-3 IFNγ CEACAM-1 EGF
GCP-2 IL-1α DR6 EGF-R
GRO IL-1β Dtk EG-VEGF
HCC-1 IL-1ra Endoglin FGF-4
HCC-4 IL-2 ErbB3 FGF-7
IL-9 IL-4 E-Selectin GDF-15
IL-17F IL-5 Fas GDNF
IL-18 BPa IL-6 Flt-3L GH
IL-28A IL-6sR GITR HB-EGF
IL-29 IL-7 HVEM HGF
IL-31 IL-8 ICAM-3 IGFBP-1
IP-10 IL-10 IL-1 R4 IGFBP-2
I-TAC IL-11 IL-1 RI IGFBP-3
LIF IL-12p40 IL-2 Rg IGFBP-4
LIGHT IL-12p70 IL-10 Rb IGFBP-6
Ltactin IL-13 IL-17R IGF-I
MCP-2 IL-15 IL-21R Insulin
MCP-3 IL-16 LIMPII MCF R
MCP-4 IL-17 Lipocalin-2 NGF R
MDC MCP-1 L-Selectin NT-3
MIF MCSF LYVE-1 NT-4
MIP-3a MIG MICA OPG
MIP-3b MIP-1a MICB PDGF-AA
MPIF-1 MIP-1b NRG1-b1 PIGF
MSPa MIP-1d PDGF Rb SCF
NAP-2 PDGF-BB PECAM-1 SCF R
OPN RANTES RAGE TGFa
PARC TIMP-1 TIM-1 TGFb1
PF4 TIMP-2 TRAIL R3 TGFb3
SDF-1a TNFa Trappin-2 VEGF
TARC TNFb uPAR VEGF R2
TECK TNF RI VCAM-1 VEGF R3
TSLP TNF RII XEDAR VEGF-D
Abbreviations/Definitions: Supplemental Table 1.
determine whether age of patient or postmortem interval (PMI)
were covariants for eachmeasure, data from each protein was also
analyzed by Analysis of Covariance (ANCOVA) with age, PMI,
or age and PMI as covariants using Medcalc statistical software
(Medcalc Software, Ostend, Belgium). Further analyses included
correlation analyses, stepwise logistic regression analyses and
receiver operating characteristic (ROC) curve analyses and were
carried out using MedCalc. For each measure, P < 0.05 was
considered statistically significant.
RESULTS
Characterization of Samples
The samples were selected based on consensus clinical and
neuropathological criteria, but as shown in Table 1, there were
different amounts of age-associated pathology in the samples.
The control samples were free of LB pathology; while the ILBD
and PD cases had varying degrees (Table 1). To support the
clinical and neuropathological criteria used for case selection,
samples were characterized for TH levels as an additional index
of disease severity. There was significant variability between the
samples in each disease group for TH, especially within the
control groups (Figure 1). In SN, disease group differences in TH
levels did not reach statistical significance by One-way ANOVA
(Figure 1A), while in striatum, expected TH differences between
each of the disease groups were shown (Figure 1B). Age and PMI
were not significant covariant factors affecting TH levels in SN or
striatum. Pathological variability within the disease groups was
also highlighted by measures of gliosis and inflammation. GFAP
levels showed no significant differences between disease groups
for SN (Figure 1C) or striatum (Figure 1D) samples; however,
GFAP levels in striatum were significantly affected by PMI (P =
0.03). There was significant negative correlation between TH
and GFAP levels in striatum (Pearson r = −0.399, P =
0.0071; Figure 1E) suggesting increased gliosis as PD pathology
progresses.Western blots measures of themicroglial marker IBA-
1 in SN (Figure 1F) and striatum (data not shown) did not show
significant disease group differences; these measures were not
affected by age or PMI.
Inflammatory Profiling of SN and Striatum
Initial data analysis of results from the Quantibody arrays
consisted of individual ANOVA for each protein measure
between the three disease groups for each of the brain regions.
Results are shown in Table 3, which lists all P-values between
groups for each protein. These results were not corrected for
multiple comparisons. Table 3 also identifies the proteins that
gave negative values for each brain region. A negative designation
was applied when fewer than 10 samples out of the total analyzed
were above the limit of detection (LOD). For striatum samples,
57 of the 158 proteins measured were considered negative, while
for SN, the same 57 were negative along with an additional 20
proteins (Table 3).
Protein Profile of SN
There were four proteins [IL-5, IL-15, monokine induced by
gamma interferon (MIG) and IL-6 soluble receptor (IL6sR)] that
gave P < 0.05 values between disease groups. The individual
results for these proteins are shown as scatter plots in Figure 2.
There were increases of IL-5, IL-15, and MIG, and a decrease of
IL-6sR, in PD samples compared to controls or ILBD samples.
Disease group differences did not become significantly different
for any of these measures when corrected for age or PMI
by ANCOVA; however, this analysis showed that IL-15 levels
were significantly affected by PMI (ANCOVA—P = 0.040). In
addition, when platelet derived growth factor (PDGF)-BB levels
were corrected for age (P = 0.031—ANCOVA), a significant
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FIGURE 1 | Relative levels of tyrosine hydroxylase, glial fibrillary acidic protein or IBA-1 in substantia nigra. (A,B) Relative levels of tyrosine hydroxylase
(TH) in control (Con), incidental Lewy body disease (ILBD), and Parkinson’s disease (PD) samples of SN (A) or striatum (B) determined by western blot measures of TH
with normalization for levels of β-actin. Statistical analysis by One-way analysis of variance (ANOVA) with Fisher LSD post-hoc test for between group differences.
(C,D) Relative levels of glial fibrillary acidic protein (GFAP) in control (Con), incidental Lewy body disease (ILBD), and Parkinson’s disease (PD) samples of SN (C) or
striatum (D) determined by western blot measures of GFAP with normalization for levels of β-actin. Statistical analysis by One-way analysis of variance (ANOVA)
showed no significance between disease groups. (E) Linear regression plot showing relation between striatum TH and striatum GFAP levels. Pearson correlation
analysis showed significance between these measures (R = −0.399, P = 0.0071). (F) Relative levels of IBA-1 in control (Con), incidental Lewy body disease (ILBD),
and Parkinson’s disease (PD) samples of SN determined by western blot measures of with normalization for levels of β-actin. Statistical analysis by One-way analysis
of variance (ANOVA) showed no significant difference between disease groups.
disease group difference was obtained (P = 0.0323 between ILBD
and PD samples).
Stepwise logistic regression analysis of these four cytokines
was carried out to determine if these measures had predictive
value between disease groups. Comparing control to PD
indicated that only IL-5 values had significant predictive value
(P = 0.003) with ROC curve analysis for IL-5 with sensitivity of
85.7% and specificity of 62.5% with area under curve (AUC) of
0.81. Further stepwise logistic regression analysis between ILBD
and PD values showed a combination of IL-15 and IL-6sR levels
gave predictive value (P = 0.0016), with ROC AUC of 0.820,
and sensitivity of 85.7% and specificity of 64.7%. These stepwise
regression analysis models were not strengthened by inclusion of
TH values. Results are summarized in Table 4. Multiple stepwise
regression analyses for all measured proteins in SN showed
no additional proteins or group of proteins could discriminate
between control and ILBD cases, or between ILBD and PD cases
(data not shown).
Protein Profile of Striatum
A panel of 13 proteins was shown to have significant differences
in striatum samples between the disease groups by One-
way ANOVA (Table 3)—CCL28 (C–C motif ligand 28 or
mucosae-associated epithelial chemokine), HCC-1 (CCL-14),
IL-18 binding protein a (IL-18BPa), PF4 (platelet factor 4),
interferon-gamma (IFN-γ), IL-1 receptor antagonist (IL-1ra),
IL-2, IL-15, PDGF-AA, PDGF-BB, TNF-α, Dtk (tyrosine-protein
kinase receptor TYRO3), and ErbB3 (also HER3, human
epidermal growth factor receptor 3). The individual scatter plot
results for these proteins are shown in Figure 3. When correcting
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TABLE 3 | Summary of One-way ANOVA results.
Array Array Array Array
CHE SN Striatum CYTO SN Striatum REC SN Striatumm GF SN Striatum
6Ckine Neg Neg BLC Neg Neg 4-1BB Neg Neg AR 0.76 0.756
Axl 0.179 0.643 Eota xin Neg Neg ALCAM 0.836 0.527 BDNF 0.295 0.709
BTC Neg Neg Eotax in-2 Neg Neg B7-1 Neg Neg bFGF Reject Reject
CCL28 0.503 0.013 G-CSF Neg Neg BCMA Neg Neg BMP-4 0.349 0.671
CTACK Neg Neg GM-CSF Neg Neg CD14 0.928 0.521 BMP-5 Neg Neg
CXCL16 0.478 0.352 I-309 Neg Neg CD30 Neg Neg BMP-7 Neg Neg
ENA-78 Neg 0.156 ICAM-1 0.621 0.83 CD40 L Neg Neg b-NGF Neg 0.867
Eotaxin-3 Neg Neg IFNg 0.832 0.044 CEACAM-1 0.941 0.655 EGF 0.406 0.79
GCP-2 Neg Neg IL-1α Neg Neg DR6 Neg 0.967 EGF-R 0.77 0.483
GRO 0.575 0.289 IL-1β Neg Neg Dtk 0.539 0.031 EG-VEGF 0.465 0.049
HCC-1 0.336 0.045 IL-1ra 0.671 0.002 Endoglin 0.935 0.299 FGF-4 Neg Neg
HCC-4 Neg Neg IL-2 0.244 0.028 ErbB3 0.252 0.004 FGF-7 Neg 0.948
IL-9 Neg Neg IL-4 Neg 0.103 E-Selectin 0.496 0.582 GDF-15 0.218 0.401
IL-17F Neg Neg IL-5 0.035 0.132 Fas 0.631 0.772 GDNF 0.766 0.394
IL-18 BPa 0.822 0.015 IL-6 0.219 0.067 Flt-3L 0.965 0.63 GH 0.663 0.397
IL-28A Neg Neg IL-6sR 0.022 0.187 GITR 0.435 0.669 HB-EGF Neg 0.83
IL-29 Neg Neg IL-7 0.631 0.146 HVEM 0.357 0.669 HGF 0.426 0.274
IL-31 Neg Neg IL-8 0.272 0.154 ICAM-3 0.103 0.073 IGFBP-1 0.553 0.192
IP-10 Neg 0.41 IL-10 Neg Neg IL-1 R4 Neg 0.277 IGFBP-2 0.731 0.316
I-TAC Neg 0.91 IL-11 Neg Neg IL-1 RI Neg 0.839 IGFBP-3 0.147 0.639
LIF Neg Neg IL-12p40 Neg Neg IL-2 Rg Neg 0.72 IGFBP-4 Reject Reject
LIGHT Neg Neg IL-12p70 Neg Neg IL-10 Rb 0.991 0.344 IGFBP-6 0.565 0.783
Ltactin 0.788 0.723 IL-13 0.231 0.091 IL-17R 0.345 0.336 IGF-I 0.097 0.391
MCP-2 0.524 0.482 IL-15 0.033 0.009 IL-21R 0.319 0.669 Insulin Neg Neg
MCP-3 0.887 0.753 IL-16 0.719 0.092 LIMPII 0.996 0.541 MCF R 0.389 0.32
MCP-4 Neg Neg IL-17 Neg Neg Lipoca lin-2 0.795 0.253 NGF R 0.183 0.309
MDC Neg Neg MCP-1 0.081 0.295 L-Selectin 0.669 0.827 NT-3 Neg Neg
MIF 0.883 0.477 MCSF 0.105 0.513 LYVE-1 0.781 0.988 NT-4 Neg 0.442
MIP-3a Neg 0.544 MIG 0.017 0.389 MICA 0.809 0.422 OPG Neg 0.363
MIP-3b Neg Neg MIP-1a Neg Neg MICB Neg Neg PDGF-AA 0.14 0.002
MPIF-1 Neg Neg MIP-1b Neg Neg NRG1-b1 Neg Neg PIGF Neg Neg
MSPa Neg Neg MIP-1d Neg Neg PDGF Rb 0.154 0.999 SCF Neg 0.641
NAP-2 0.52 0.178 PDGF-BB 0.078 0.003 PECAM-1 0.394 0.184 SCF R 0.748 0.89
OPN 0.579 0.558 RANTES 0.65 0.109 RAGE Neg 0.911 TGFa Neg Neg
PARC Neg Neg TIMP-1 0.599 0.243 TIM-1 Neg 0.871 TGFb1 Neg Neg
PF4 0.829 0.02 TIMP-2 0.184 0.08 TRAIL R3 0.754 0.839 TGFb3 Neg Neg
SDF-1a Neg Neg TNFa 0.144 0.008 Tra ppin-2 Neg 0.119 VEGF Neg 0.999
TARC Neg Neg TNFb Neg Neg uPAR 0.078 0.533 VEGF R2 Neg 0.775
TECK Neg Neg TNF RI 0.179 0.545 VCAM-1 0.432 0.21 VEGF R3 Neg 0.21
TSLP Neg Neg TNF RII 0.508 0.517 XEDAR Neg Neg VEGF-D Neg 0.814
Results represent P-values from One-way analysis of variance for the comparison of values between Control, ILBD, and PD disease groups. Neg means the protein was deemed not
to be present in sufficient number of the samples (we assessed this as <10 positive samples out of the 55 SN or 52 striatum). Measures with P values < 0.05 are highlighted in bold.
values for age, PMI, or age and PMI by ANCOVA, the disease
group differences for these 13 proteins remained significant (P <
0.05). With these corrections, no additional proteins reached
statistical significance.
Stepwise logistic regression analysis of these measures
identified a combination of the values for ErbB3, IL-2, and PF4
as having predictive value between control and PD cases (P =
0.0001). Analysis by ROCwith all three factors showed sensitivity
of 86.67% and specificity of 87.5%, and an AUC of 0.917. As
expected, TH values alone had significant predictive value for
discriminating control from PD cases (P = 0.0001) with ROC
analysis showing sensitivity of 80%, specificity of 85.71%, and
AUC 0.914. Including TH values with the 13 proteins in step-
wise regression analysis produced a different outcome; CCL28
in combination with TH had significant predictive value (P <
0.0001), with sensitivity of 80%, specificity of 78.7%, and AUC
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FIGURE 2 | Scatter plots showing distribution of results for proteins that showed disease group differences in substantia nigra samples. Disease group
differences for interleukin-5 (IL-5) (A), IL-15 (B), monokine induced by gamma interferon (MIG) (C), and IL-6 soluble receptor (IL-6sR) (D). Statistical analysis by
One-way analysis of variance (ANOVA) with Fisher LSD post-hoc test for between group differences.
TABLE 4 | Sensitivity and specificity for discriminating between disease groups.
Measures Disease groups % Sensitivity (95% CI) % Specificity (95% CI) Area under curve P
(SN) IL-5 Control/PD 75 61.1 0.73 0.026
(SN) IL-15, IL-6sR ILBD/PD 85.7 62.5 0.82 0.0016
(Str) ErbB3, IL-2, PF4 Control/PD 86.7 87.5 0.92 0.0001
(Str) TH Control/PD 80 85.7 0.91 0.0001
(Str) TH, CCL28 Control/PD 80 78.7 0.94 <0.0001
(Str) PDGF-AA ILBD/PD 72.2 62.5 0.72 0.015
(Str) TH, IL-15 ILBD/PD 82.3 85.7 0.90 0.0003
(Str) PDGF-AA Control/ILBD 66.7 77.8 0.81 0.0014
(Str) TH Control/ILBD 60 70.6 0.737 0.0157
of 0.938. Repeating the logistic regression analysis to determine
if any of these measures gave predictive value between ILBD
and PD cases identified PDGF-AA, with ROC analysis showing
sensitivity of 72.2% and specificity of 62.5% and AUC of 0.722
(P = 0.015). Combining TH values with the 13 proteins showed
IL-15 and TH values could discriminate between ILBD and
PD (P = 0.0003), with sensitivity of 82.35 % and specificity
of 85.71%, and AUC of 0.899. PDGF-AA levels alone gave
discrimination between control and ILBD samples (P = 0.0014)
with ROC analysis showing sensitivity of 66.67%, specificity
of 77.78%, and AUC of 0.811. TH values alone discriminated
between control and ILBD samples (P = 0.0157, sensitivity of
60%, specificity of 70.59%, and AUC of 0.737). Summary of these
findings are shown in Table 4.
Correlation Analyses between Measures
Multiple correlation analyses were carried out for proteins
that showed significant One-way ANOVA differences to
indicate if levels of any of these correlated with each other.
In SN, IL-5, IL-15, and MIG levels positively correlated
with each other, while IL-6sR did not correlate with any
measure (Table 5). This suggests that in samples showing
inflammatory activation, a network of similar factors become
upregulated. Significant correlations between some of the
striatum proteins were identified (Table 6). Proinflammatory
cytokines in this table showed significant positive correlations
with each other, while there was also significant positive
correlation between the PDGF-AA and PDGF-BB. The
negative correlations between PDGF-BB, and IFN-γ or
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FIGURE 3 | Scatter plots showing distribution of results for proteins
that showed disease group differences in striatum samples. Disease
(Continued)
FIGURE 3 | Continued
group differences for platelet derived growth factor-AA (PDGF-AA) (A), ErbB3
(B), PDGF-BB (C), and Dtk (D). HCC-1, (E), platelet factor-4 (PF4) (F), IL-1
receptor antagonist (IL-1RA) (G), IL-2 (H), IL-15 (I), TNF-α (J), CCL-28 (K),
IFN-γ (L), IL-18 binding protein (IL-18bpa) (M). Statistical analysis by One-way
analysis of variance (ANOVA) with Fisher LSD post-hoc test for between group
differences.
TABLE 5 | Correlation between significant protein measures and with TH
in substantia nigra.
IL-15 IL5 MIG IL-6SR
TH (R) 0.315 0.151 0.133 −0.075
(P) 0.029 0.306 0.367 0.61
IL-15 0.737 0.488 −0.191
<0.0001 0.0002 0.166
IL-5 0.656 −0.254
<0.0001 0.064
MIG −0.177
0.195
(R), Pearson correlation coefficient. (P), P values. Values highlighted in bold indicate
statistically significant correlation between measures.
TNF-α suggested that the levels of this growth factor were
affected by inflammation; this was not observed for PDGF-AA
(Table 6).
Correlation Analysis of All Measured Array
Features with TH
Multiple correlation analyses were carried out for all of the
SN measures against TH levels. The significant correlations are
shown in Table 7. Although CD14 and urokinase plasminogen
activator receptor (uPAR), two classical markers of inflammation,
did not show significant disease group differences, levels of
the inflammation-associated markers negatively correlated with
TH levels. The same analysis carried out for all striatal
measures compared to striatum TH levels (Table 7) only
showed significant positive correlations with activated leukocyte
cell adhesion molecule (ALCAM-1), platelet-endothelial cell
adhesion molecular (PECAM-1) and endoglin, all considered
vascular adhesion proteins. The one common molecule from
both brain regions was PECAM-1, which is involved in
the integrity of the cerebral vasculature. To further assess
inflammatory changes, we also measured levels of the astrocytic
marker GFAP and the microglial markers IBA-1 and TLR-2
in samples by western blots. As had been shown (Figure 1D),
the values between groups for GFAP in striatum were not
statistically different (Figure 1D), but analysis of TH and GFAP
across all disease groups did show significant negative correlation
(R = −0.399, P = 0.0071; Figure 1D). Further separating
these values into disease groups gave significant correlation
between the control group GFAP values and TH (R = −0.551,
P = 0.0219), but not between TH and GFAP levels for
the ILBD or PD groups. There were no correlations between
TH levels in SN and levels of IBA-1 or TLR-2 (data not
shown).
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TABLE 6 | Significant Correlation between key protein measures in
striatum.
Dtk ErbB3
CCL28 (R) 0.50 0.47
(P) 0.0002 0.0007
Dtk
ErbB3 (R) 0.79
(P) <0.0001
PDGF-AA PF4
HCC-1 (R) 0.46 0.37
(P) 0.0009 0.008
IL-2 IL-15 IFN-γ PDGF-BB TNF-α
IL-1ra (R) 0.70 0.53 0.76 −0.385 0.566
(P) <0.0001 0.0001 <0.001 0.0063 <0.0001
IL-15 IFN-γ PDGF-BB TNF-α
IL-2 (R) 0.86 0.65 −0.45 0.80
(P) <0.0001 <0.0001 0.0012 <0.0001
IFN-γ PDGF-BB TNF-α
IL-15 (R) 0.56 0.42 0.74
(P) 0.0002 0.0026 <0.0001
PDGF-BB
IFN-γ (R) −0.442
(P) 0.0015
PDGF-BB PF4
PDGF-AA (R) 0.681 0.292
(P) <0.0001 0.0418
PF4 IL-18 BPa TNFa
PDGF-BB (R) 0.46 0.34 −0.35
(P) 0.0008 0.016 0.0128
TNFa
IL-18BPa (R) −0.284
(P) −0.048
TLR-2 Expression in SN
To follow up on the findings from a recent paper that
examined tissue sections of SN from control, ILBD and PD
cases and showed early increased expression of TLR-2 (Doorn
et al., 2014), we carried out biochemical measurement of
TLR-2 by western blot in our SN samples. Our analyses
showed no significant differences between disease groups, but
data obtained indicated TLR-2 levels had strong correlation
with a number of the inflammatory markers measured
(Table 8).
Microglial Activation Profiles in SN and
Striatum
We stained tissue sections of SN and striatum from representative
control, ILBD and PD cases to characterize activated microglia
present in the disease groups. Staining was carried out using
TABLE 7 | Significant Correlations between protein measures and TH.
Substantia nigra TH Striatum TH
CD14 (R) −0.306 ALCAM (R) 0.308
(P) 0.036 (P) 0.0375
CEACAM 0.461 Endoglin 0.401
0.001 0.0057
EG-VEGF 0.674 PECAM-1 0.347
< 0.0001 0.0183
EGFR 0.521 GFAP −0.528
0.0001 0.0002
GDNF 0.313
0.030
IL-13 0.43
0.0023
IL-15 0.315
0.029
Lipocalin-2 −0.366
0.011
LYVE-1 −0.366
0.010
PECAM-1 0.371
0.0094
SCF-R 0.731
< 0.0001
TNF-α 0.411
0.0037
uPAR −0.299
0.039
R, Pearson R correlation coefficient. See supplemental Table 1 for abbreviations for
proteins.
antibody LN3, which recognizes the MHCII protein HLA-DR,
and antibody IBA-1, which recognizes all microglia. Results show
increased immunoreactivity for HLA-DR in microglia associated
with neuromelanin-containing neurons in the SN pars compacta,
even in control cases (Figures 4A,B), with progressive change in
microglial morphology in ILBD (Figures 4C,D), and PD cases
(Figures 4E,F). The presence of smaller numbers of intensely-
stained activated microglia in the control cases (Figures 4A,B)
suggest ongoing inflammation even in the absence of disease.
A noticeable feature was a difference within the PD groups,
where some cases appeared to have a very strong inflammatory
response in the vicinity of SN neurons (Figures 4E,F), while in
others, there was a noticeable reduction in number of activated
microglia (Figures 4G,H). Immunohistochemistry with antibody
IBA-1 reveals greater numbers of microglia, but did not
discriminate activated microglia in these sections (data not
shown). For striatum, the sections were double-stained with
antibody to TH (brown) to reveal the location of positive fibers.
In control striatum, there were TH positive fibers throughout
the structure, while in the PD cases, most of the TH fibers were
lost. In Figures 4J–L particularly intense microglial response
was observed in the vicinity of surviving TH fibers. Again,
HLA-DR-positive microglia were also seen in control striatum
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FIGURE 4 | Immunohistochemistry of microglia in tissue sections of SN and striatum. Substantia nigra: Immunohistochemical staining of sections from
Control (A,B), ILBD (C,D), and PD (E,F) and PD (G,H) from SN tissue sections. (A,C,E,G) are lower magnification of SN tissue sections showing progressive increase
in intensity of HLA-DR immunoreactive microglia (purple) from (A–E), but PD case (G) showed reduced microglia intensity (burnt-out pathology) consistent with loss of
SN neurons. Higher magnification images (B,D,F,H) illustrate the changes in morphology of microglia with progressive activation with reduction in burnt-out PD case.
(H) shows microglia associated free neuromelanin. The preferential association of activated microglia with neuromelanin-containing dopaminergic neuron is apparent
in all sections, even those from control cases. Striatum: Immunohistochemical staining of sections of Control (I,J) and PD (K,L) from striatum (putamen) stained with
antibody LN3 to HLA-DR (purple) and tyrosine hydroxylase (brown). Control case (I,J) show association of microglia with tyrosine hydroxylase positive fibers. Stronger
HLA-DR immunoreactivity (K) and activated morphology is apparent in association with remaining TH positive fibers in PD case (K,L). Representative staining of
sections from cases included in the antibody array series and are representative of each group.
sections (Figures 4I,J), though with a less-activated morphology
compared to those in PD cases (Figures 4K,L).
Does the Presence of AD-Type Pathology
in Brains Affect Inflammatory Protein
Levels?
One limitation of human disease-focused studies can be the
presence of mixed pathologies within the same tissue samples.
For this study, the possible effects of age-associated AD-type
pathology, namely plaques and tangles, on the inflammatory
environment might be a confound factor. Although the primary
diagnoses criteria used for case selection was the presence or
absence of PD, along with the absence of AD, age-associated
pathology was a feature of many of the cases used (Table 1).
As the routine neuropathology diagnosis of each donor brains
included an assessment of the overall burden of AD-type
pathology by assessing the plaque and tangle scores of each brain,
we used the above scores to identify any correlations of individual
SN and striatum array measures with plaque and tangle scores
using Spearman rank correlation analysis (Table 9). Proteins Dtk,
ErBb3, IL-1ra, and IL-5 that had shown significant disease group
differences in the antibody arrays for striatum showed significant
correlations with tangle scores (Table 9, bold).
DISCUSSION
This work is the first description of large-scale unbiasedmultiplex
quantitative protein profiling of tissue from human SN and
striatum to elucidate changes in inflammatory and related
molecules that might be involved in PD pathology, though this
platform was used to screen sera from patients with Parkinsonian
syndromes for inflammatory protein changes (Mahlknecht et al.,
2012).Wemeasured the levels of 158 different proteins in SN and
striatum samples from control, ILBD, and PD cases. The study
was based on the hypothesis that inflammatory molecules that
become upregulated in ILBD cases might be more likely involved
in disease mechanisms. ILBD seems to represent a precursor
stage to PD; these subjects have no diagnosed movement
disorders or dementia, but certain amounts of LB pathology, loss
of dopaminergic neurons and reduced levels of TH (Beach et al.,
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TABLE 8 | Significant correlations between key protein measures and
TLR-2 in substantia nigra.
TLR-2
IBA-1 (R) 0.565
(P) 0.0003
CD14 0.434
0.0045
CXCL16 0.38
0.0142
HCC-1 0.568
0.0001
HGF 0.422
0.0059
IL-2 0.377
0.0152
IL-5 0.372
0.0166
MCP-1 0.531
0.0004
TNF-RII 0.643
< 0.0001
TRAIL-R3 0.362
0.0201
R, Pearson R correlation coefficient. See Supplemental Table 1 for abbreviations for
proteins.
2008; Caviness et al., 2011; Iacono et al., 2015). In agreement with
our earlier studies, we showed this group of tissue samples had
intermediate TH values between control and PD cases in striatum
(Beach et al., 2008, 2009).
The major findings from this study were the identification
of candidate inflammatory or growth factor molecules that
showed significant disease group differences. We identified four
proteins in SN, and 13 proteins in striatum that had One-way
ANOVA differences, and post-hoc differences between disease
groups with P < 0.05, though these statistical analysis did
not take account for multiple comparisons. The other feature
of the study was the identification of a different inflammatory
signature for SN compared to striatum. The only molecule
that changed significantly for both brain regions was IL-5.
Independent validation of these findings are now required using
sensitive methodologies in a new group of tissue samples.
An inherent limitation to the approach using human tissues
was the highly variable nature of disease and inflammatory
changes within each group. This large variability for many
measures reduced the potential of detecting disease group
differences. As demonstrated in Figure 1, there was considerable
variability in the values for TH as the fundamental biochemical
measure of disease severity. This could also be seen in most
individual measures (see scatter plots in Figures 2, 3 as examples)
particularly within the control groups. Related to this was
sensitivity of detection for certain proteins. It was observed that
a number of samples within each group had values below the
LOD of the assays. Although this was observed for IL-5, IL-15,
and MIG in SN, and IL-2, TNF-α, IL1-RA, IL-15, and IFN-γ in
TABLE 9 | Correlations between Alzheimer’s-type pathology and protein
measures.
Plaques Tangles
Protein R P Protein R P
SUBSTANTIA NIGRA
ALCAM −0.335 0.012 Dtk −0.276 0.041
CCL28 0.441 0.0008 PDGF-AA −0.303 0.024
CD14 −0.381 0.004
Endoglin −0.416 0.002
ErbB3 −0.323 0.016
Flt-3L −0.324 0.016
IL-18Bpa 0.361 0.007
PDGF-AA −0.271 0.045
PECAM-1 −0.343 0.010
PF4 0.277 0.041
uPAR −0.299 0.027
STRIATUM
L-tactin −0.352 0.013 AR 0.346 0.015
MCP-2 −0.34 0.017 Dtk −0.462 0.0008
MIP-3a −0.415 0.003 ErbB3 −0.397 0.005
OPN −0.311 0.029 FGF-7 0.299 0.037
Trappin-2 −0.308 0.031 IL-1ra 0.29 0.043
uPAR −0.317 0.026 IL-5 0.295 0.039
IP-10 0.36 0.011
NT-4 0.458 0.0009
Plaques, Histological plaque score 0-15; Tangles, Histological tangle score 0-15; R,
Spearman rank correlation. See Supplemental Table 1 for abbreviations for proteins.
Results in bold identify proteins that showed significant differences between control, ILBD,
and PD groups.
striatum (Figures 2, 3), a clear increase in the number of PD
samples having higher positive values was apparent, confirming
the changes in these cytokines in the diseased samples.
The analyses of protein levels showed a higher percentage
of proteins being below the LOD in SN compared to striatum.
Of the 158 array proteins being measured, 101 of these
proteins could be detected and measurable in striatum, while
81 were measurable in SN. The difference in protein profiles
between SN and striatum did not appear to be due to
different sensitivity between tissues. All of the proteins that
showed significant differences between disease groups in striatum
samples could be detected in SN, while the reverse situation was
present for significant SN proteins in striatum (Table 3). This
feature provided support for the observation of differences in
inflammatory features between SN and striatum.
Fundamental to this study was also a demonstration of
differences in appearance of microglia in disease-affected tissues.
Immunohistochemical staining of selected tissue sections of
SN and striatum for the presence of morphologically activated
microglia using antibody LN3 identified a progressive change in
appearance of microglia associated with increasing pathology.
This was particularly apparent in SN; however, two patterns
of activated microglia could be seen in PD cases. Some cases
had large numbers of highly-activated microglia potentially
indicative of an active pathological process; while others showed
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a reduced number of microglia with many having intracellular
neuromelanin potentially indicative of “burnt-out” pathology
(Figures 4G,H compared to Figures 4E,F). Similar patterns were
apparent in striatum in association with TH positive fibers. One
noticeable feature was the presence of considerable numbers of
activated microglia in SN and striatum from control cases that
had absence of LB pathology.
There were two patterns of changes in proteins between
disease groups. For those proteins that had reduced levels
with progression to PD, this could indicate loss of “protective”
functions as a disease feature. For those proteins that showed
increased levels with progression to PD, this indicated a possible
role in enhancing inflammatory pathology. In SN, there were
increases in PD for cytokines IL-5, IL-15, and MIG, but decrease
in levels of IL-6sR. In striatum, there were decreases in PD
compared to control for PDGF-AA, PDGF-BB, ErbB3, Dtk,
PF4 and HCC-1, IL-18BPa and CCL28, but increases in PD
for cytokines IL-2, IFN-γ, TNF-α, IL-1Ra, and IL-15. The
factors downregulated are either inflammatory antagonists or
growth factors, while the factors upregulated are inflammation-
associated cytokines. With the exception of IL-2, TNF-α, and
IFN-γ, the other factors we identified have not been associated
with PD in previous animal or human studies.
Of the highlighted proteins, some features as they relate
to possible brain function will be discussed. IL-5 has been
described as a Th2-cell cytokine whose expression is upregulated
in inflammatory-associated conditions associated with parasitic
infections, similar to IL-4 or IL-13, with secretion of IL-5
by astrocytes and microglia having been described (Sawada
et al., 1993). IL-5 can also be a colony stimulating factor
for macrophages and microglia (Ringheim, 1995; Liva and de
Vellis, 2001). By comparison, IL-15 expression in diseased brain
has been more widely studied than IL-5. Both neurotoxic and
proinflammatory consequences of IL-15 have been observed in
brain. IL-15 receptors are present on neurons, and treatment of
neurons in vivowith IL-15 resulted in reduced neurite outgrowth
and reduction in expression of microtubule-associated brain
(MAP)-2 (Huang et al., 2009). IL-15 can enhance the cytotoxic
potential of CD4+ T cells inmultiple sclerosis (Broux et al., 2015).
IL-15 also has an effect at the blood-brain barrier resulting in
weakening of tight junctions and increased permeability (Stone
et al., 2011). Increased expression of MIG by microglia in brain
has been demonstrated in response to IFN-γ and also IL-9
(Carter et al., 2007; Ellis et al., 2010; Ding et al., 2015). MIG
activates cellular signaling through the receptor CXCR3, which
is shared with CXCL10 (interferon gamma induced protein 10–
IP-10). Compared to MIG, IP10 was not consistently detected
in SN samples. Interpreting the decrease in levels of IL-6sR in
PD compared to ILBD samples is complex as IL-6sR functions
can have both agonist and antagonist properties. IL-6 interaction
with IL-6sR interaction enhances signaling on cells expressing
the other IL-6 receptor gp130, while blocking signaling on cells
expressing both IL-6R and gp130. Microglia express IL-6R as well
as gp130 so changes in IL-6sR levels might block rather than
enhance activation of microglia. However, other studies have
shown that IL-6 signaling in brain is predominantly enhanced by
IL-6sR (Burton et al., 2011, 2013; Campbell et al., 2014).
The different pattern of changes for proteins were observed in
striatum compared to SN was suggestive of a decline in growth
factors along with enhanced levels of different inflammatory
proteins were ongoing. Both PDGF-AA and PDGF-BB levels
showed disease differences in striatum. It has been known
that PDGF can be neurotrophic for transplanted dopaminergic
neurons and induces neurogenesis (Smits et al., 1993; Mohapel
et al., 2005). Clinical trials using intraventricular infusion of
PDGF-BB in PD patients as a therapeutic treatment to support
dopaminergic neurons are ongoing (Paul et al., 2015). In Table 5,
the significant negative correlations of PDGF-BB levels with
those of inflammatory markers IL-1RA, IL-2, IL-15, IFN-γ, and
TNF-α suggested that levels were negatively affected by degree of
inflammatory activation. The correlation between PDGF-BB and
TH levels in striatum was close to significance (P = 0.052). CCL-
28 is expressed by epithelial cells and has chemotactic properties
for certain immune cells. Increased expression in periphery has
been associated with inflammation, however, in brain, it has only
been identified in neurons rather than glial cells (Liu et al., 2012).
In a model of epilepsy, downregulated expression of CCL28 was
associated with loss of neurons (Liu et al., 2012). Dtk (receptor
tyrosine kinase TYRO3) is also predominantly expressed by
neurons (Prieto et al., 2007; Zhao et al., 2012). Its function in
the PD brain is unclear, but overexpression of Dtk in an AD
mouse model resulted in reduced production of amyloid beta
(Aβ) peptide (Zheng et al., 2012). Interleukin-18 binding protein
α (IL-18BPa) is high-affinity antagonist for the proinflammatory
cytokine IL-18 (interferon gamma inducing factor). Both factors
normally occur in balance, but a decrease in IL-18BPa can be
accompanied with increased IL-18 (Dinarello et al., 2013). This
factor has not been studied in human brain Platelet factor 4
(PF4), also known as CXCL4, is a chemokine involved in wound
repair and inflammation. It has anti-angiogenic properties, and
is an antagonist for the basic fibroblast growth factor receptor
(Sulpice et al., 2002; Chadderton and Stringer, 2003). ErbB3 is
an epidermal growth factor-related receptor tyrosine kinase with
neuregulin as a ligand. ErbB3 is widely expressed in brain in gray
matter, white matter, neurons, astrocytes, endothelial cells, and
oligodendrocytes (Ozaki et al., 1998; Steiner et al., 1999; Calaora
et al., 2001; Lok et al., 2009; Sharif et al., 2009). Examination
of human PD striatum samples for EGF and ErbB receptors 1-
4 demonstrated different results from this study (Iwakura et al.,
2005). A decrease of EGF in PD samples was reported, along with
a decrease in ErbB1 and ErbB2, but not ErbB3 (Iwakura et al.,
2005).We did not identify differences in EGF levels in striatum or
SN samples in this study. HCC-1 (CCL-14) has not been studied
in brain, but has been characterized as a marker for alternatively
activated/anti-inflammatorymacrophages (Jaguin et al., 2013). In
the striatum samples, there was a significant increase between
ILBD and PD samples.
Five of the inflammatory cytokines associated with disease
differences were progressively upregulated in striatum
between control, ILBD, and PD samples. IFN-γ is a potent
proinflammatory cytokine primarily produced by T lymphocytes
and natural killer cells rather than by brain resident cells. IFN-γ
has been shown to have a central role in mediating dopaminergic
cell loss or deterioration of the nigrostriatal pathway in PD
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animal models (Mount et al., 2007; Brochard et al., 2009;
Chakrabarty et al., 2011; Barcia et al., 2012; Mangano et al.,
2012). By contrast, IL-1RA is protective and blocks the binding
of the cytokines IL-1α or IL-1β to the IL-1 receptor. Its increased
levels are suggestive of inflammation due to elevated levels of
IL-1α or IL-1β. This cannot be confirmed in this study as IL-1α
and IL-1β were not detectable in most SN or striatum samples.
IL-1RA has significant neuroprotective properties in situations
with brain injury with increased expression by neurons in AD
and Pick’s disease brains (Yasuhara et al., 1997; Sanderson et al.,
1999; Yang et al., 1999; Vecil et al., 2000; Masada et al., 2003).
IL-2 is also a T-lymphocyte produced cytokine that is involved
in cellular immune responses mediated by T-lymphocytes.
Increased IL-2 levels were reported in an earlier study in PD
striatum (Mogi et al., 1996). TNF-α is been the cytokine most
widely implicated in the pathogenesis of PD. The majority
of studies have focused on TNF-α in various animal models
not in human brain (Nagatsu et al., 2000a; Gayle et al., 2002;
Carvey et al., 2005a; Zhao et al., 2007; De Lella Ezcurra et al.,
2010; Chertoff et al., 2011; Daniele et al., 2015). Sensitivity of
detection of this cytokine was an issue due to the number of
samples with negative values included in the analysis. However,
comparing TNF-α levels in SN control samples with control
striatum samples illustrate difference between these two brain
regions. In SN, half of the control samples had detectable levels
of TNF-α, while the striatal control samples were all below the
level of detection. As can be seen, the distribution of values
in SN between control and PD were not significantly different
(P = 0.144), while in striatum there was an increasing number
of positive samples in the ILBD and PD groups (P = 0.008).
Although the values were low, the amount of TNF-α detected in
SN was overall higher than in striatum. Mean values in PD SN
samples were 10.1 pg/ml compared to 3.5 pg/ml in striatum PD
samples.
Although interpreting the implications of these findings for
identifying therapeutic targets needs to be done with caution,
interactions of different factors and also the presence of other
pathologies needs to be considered. Correlation of SN measures
with TH levels identified one panel of 13 proteins, while a
panel of four proteins correlated with TH levels in striatum.
One common feature was the number of vascular markers—
this suggested that changes in vascular integrity could be a
feature of PD pathogenesis. Pathology-based studies have shown
increased vascular degeneration in PD affected brain tissue, as
well as aberrant angiogenesis that also can promote vascular
degeneration (Desai et al., 2009; Guan et al., 2013). The possible
confounding effect of AD-type pathology also needs to be
considered when interpreting findings. It has been recently
described that many subjects diagnosed clinically with PD
show evidence of additional neuropathology upon postmortem
examination (Dugger et al., 2014). As demonstrated in Table 9,
there were significant correlations between a number of these
inflammatory proteins with plaque and tangle pathology, even
though the AD pathology measures used in our analyses did not
directly assess plaques and tangles in SN and striatum but were
used as an overall index of brain load of AD-type pathology.
In summary, we had defined different inflammatory profiles
for SN and striatum using an antibody array assay that
measured 158 different biologically active proteins in tissue from
control, ILBD, and PD cases. The study has identified candidate
molecules whose role(s) in accelerating PD pathology can be
validated in further analyses. One of the problems highlighted
in this study is the heterogeneity in disease or aging changes
in these carefully selected cases, as well as the presence of
other neuropathologies that can affect measures. Variability is
inevitable in human samples, but potentially masked some of
the disease group differences. The very large range of values
found for each of the factors suggests other causes beside PD
pathology might be affecting levels of molecules in tissue. The
use of correlation analyses along with assessment of disease
group differences provided interesting leads to follow up. The
strength of this application is the quality of the postmortem tissue
used. These were collected and stored under defined conditions
with short postmortem delays so the stability of these measured
molecules should be assured (Beach et al., 2015). Further studies
though will require methodology with higher sensitivity to be
able to measure the low levels of key cytokines in all tissue
samples.
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